Do structured products deserve to be in the firing line again?

katrina Baugh
clock

Another week another damaging story for the structured products industry. The headline ‘FSA fines Credit Suisse UK £5.95m for structured product failings' undoubtedly sent terror into the hearts of investors.

They must have hoped the days of large scale problems related to these vehicles were behind them following the huge clean-up operation post-Lehmans.  However, rather than the fine relating to issues with Credit Suisse- backed products, as the headline perhaps suggests, the failings were linked to sales by its private bank of structured capital at risk products (SCARPs). So another mis-selling issue rather than a fundamental problem with the products themselves.  The fine also relates to a period between January 2007 and December 2009 – so rather than a new problem this is a retrospe...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot